STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION	(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER	(X2) MULTIPLE CONSTRUCTION	(X3) DATE SURVEY COMPLETED
	155726	A. BUILDING 00 B. WING	01/24/2023

NAME OF PROVIDER OR SUPPLIER	STREET ADDRESS, CITY, STATE, ZIP COD
RIVER TERRACE HEALTH CARE CENTER	400 CAYLOR BLVD BLUFFTON, IN 46714

(X4) ID PREFIX TAG	SUMMARY STATEMENT OF DEFICIENCIE (EACH DEFICIENCY MUST BE PRECEDED BY FULL REGULATORY OR LSC IDENTIFYING INFORMATION	ID PREFIX TAG	PROVIDER'S PLAN OF CORRECTION (EACH CORRECTIVE ACTION SHOULD BE CROSS-REFERENCED TO THE APPROPRIATE DEFICIENCY)	(X5) COMPLETION DATE
F 0000 Bldg. 00	This visit was for a Recertification and State Licensure Survey. This visit included a State Residential Licensure Survey Survey dates: January 19, 20, 23, and 24, 2023. Facility number: 003575 Provider number: 155726 AIM number: 200395060 Census Bed Type: SNF/NF: 28 Total: 28 Census Payor Type: Medicare: 1 Medicaid: 27 Total: 28 This deficiency reflects State Findings cited in accordance with 410 IAC 16.2-3.1. Quality review completed January 25, 2023.	F 0000		
F 0758 SS=D Bldg. 00	483.45(c)(3)(e)(1)-(5) Free from Unnec Psychotropic Meds/PRN Use §483.45(e) Psychotropic Drugs. §483.45(c)(3) A psychotropic drug is any drug that affects brain activities associated with mental processes and behavior. These drugs include, but are not limited to, drugs in the following categories: (i) Anti-psychotic; (ii) Anti-depressant; (iii) Anti-anxiety; and (iv) Hypnotic			

LABORATORY DIRECTOR'S OR PROVIDER/SUPPLIER REPRESENTATIVE'S SIGNATURE | TITLE | (X6) DATE

STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION	(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER	(X2) MULTIPLE CONSTRUCTION	(X3) DATE SURVEY COMPLETED
	155726	A. BUILDING 00 B. WING	01/24/2023

NAME OF PROVIDER OR SUPPLIER	STREET ADDRESS, CITY, STATE, ZIP COD
RIVER TERRACE HEALTH CARE CENTER	400 CAYLOR BLVD BLUFFTON, IN 46714

(X4) ID PREFIX TAG	SUMMARY STATEMENT OF DEFICIENCIE (EACH DEFICIENCY MUST BE PRECEDED BY FULL REGULATORY OR LSC IDENTIFYING INFORMATION	ID PREFIX TAG	PROVIDER'S PLAN OF CORRECTION (EACH CORRECTIVE ACTION SHOULD BE CROSS-REFERENCED TO THE APPROPRIATE DEFICIENCY)	(X5) COMPLETION DATE
	Based on a comprehensive assessment of a resident, the facility must ensure that--- §483.45(e)(1) Residents who have not used psychotropic drugs are not given these drugs unless the medication is necessary to treat a specific condition as diagnosed and documented in the clinical record; §483.45(e)(2) Residents who use psychotropic drugs receive gradual dose reductions, and behavioral interventions, unless clinically contraindicated, in an effort to discontinue these drugs; §483.45(e)(3) Residents do not receive psychotropic drugs pursuant to a PRN order unless that medication is necessary to treat a diagnosed specific condition that is documented in the clinical record; and §483.45(e)(4) PRN orders for psychotropic drugs are limited to 14 days. Except as provided in §483.45(e)(5), if the attending physician or prescribing practitioner believes that it is appropriate for the PRN order to be extended beyond 14 days, he or she should document their rationale in the resident's medical record and indicate the duration for the PRN order. §483.45(e)(5) PRN orders for anti-psychotic drugs are limited to 14 days and cannot be renewed unless the attending physician or prescribing practitioner evaluates the resident for the appropriateness of that medication. Based on interview and record review, the facility failed to ensure adverse side effects of psychotropic medications were monitored for 1 of	F 0758	**Plan of Correction Annual Survey and Re-Certification 1/19-1/24/2023:**	02/10/2023

STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION	(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER	(X2) MULTIPLE CONSTRUCTION	(X3) DATE SURVEY COMPLETED
	155726	A. BUILDING 00 B. WING	01/24/2023

NAME OF PROVIDER OR SUPPLIER	STREET ADDRESS, CITY, STATE, ZIP COD
RIVER TERRACE HEALTH CARE CENTER	400 CAYLOR BLVD BLUFFTON, IN 46714

(X4) ID PREFIX TAG	SUMMARY STATEMENT OF DEFICIENCIE (EACH DEFICIENCY MUST BE PRECEDED BY FULL REGULATORY OR LSC IDENTIFYING INFORMATION	ID PREFIX TAG	PROVIDER'S PLAN OF CORRECTION (EACH CORRECTIVE ACTION SHOULD BE CROSS-REFERENCED TO THE APPROPRIATE DEFICIENCY)	(X5) COMPLETION DATE
	5 residents reviewed (Resident 18). Findings include: Resident 18's record was reviewed on 1/20/2023 at 10:30 AM. Diagnoses included Alzheimer's disease with early onset, major depressive disorder, single episode, unspecified, vascular dementia, unspecified severity, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety, anxiety disorder, unspecified, major depressive disorder, recurrent severe without psychotic features, adverse effect of other antipsychotics and neuroleptics, subsequent encounter, unspecified dementia, unspecified severity, with agitation, major depressive disorder, recurrent, severe with psychotic symptoms, dementia in other diseases classified elsewhere, unspecified severity, with psychotic disturbance, generalized anxiety disorder, restlessness and agitation. A brief interview for mental status assessment, dated 11/15/2022, indicated Resident 18 had score of 3 (severe cognitive impairment). 1. A current care plan indicated Resident 18 had a behavior problem related to major depressive disorder with behaviors such as sense of hopelessness and anxiety. The goal indicated Resident 18 would have no more than 2 episodes of anxiousness each week and would not have more than 2 episode per week of feeling hopeless or feeling down through the next review. The interventions included administer medications as ordered and monitor for and document side effects and effectiveness. A physician order, dated 8/3/2022, indicated to give Buspirone HCl 5 milligram (mg) tablet (a medication used to treat anxiety- nervousness),		**R 000** By submitting the enclosed materials, we are not admitting the truth or accuracy of any specific findings or allegations. We reserve the right to contest the findings or allegations as part of any proceedings and submit these responses pursuant to our regulatory obligations. The facility request that the plan of correction be considered effective February 10, 2023 to the annual licensure survey completed January 24, 2023. The facility also requests that our plan of correction be considered for paper review compliance. The facility will submit any evidence as requested to validate compliance. **F758** **It is the practice of this facility to assure that residents are being monitored for any adverse side effects involved with taking psychotropic medications.** ***The corrective action taken for those residents found to be affected by the deficient practice include:*** Resident #18 medication records were corrected to include documentation to monitor for psychotropic side effects on the eMar and also in the nurses notes in the event of adverse side effects. ***How other residents that have the potential to be affected have***	

STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION	(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER	(X2) MULTIPLE CONSTRUCTION	(X3) DATE SURVEY COMPLETED
	155726	A. BUILDING 00 B. WING	01/24/2023

NAME OF PROVIDER OR SUPPLIER	STREET ADDRESS, CITY, STATE, ZIP COD
RIVER TERRACE HEALTH CARE CENTER	400 CAYLOR BLVD BLUFFTON, IN 46714

(X4) ID PREFIX TAG	SUMMARY STATEMENT OF DEFICIENCIE (EACH DEFICIENCY MUST BE PRECEDED BY FULL REGULATORY OR LSC IDENTIFYING INFORMATION	ID PREFIX TAG	PROVIDER'S PLAN OF CORRECTION (EACH CORRECTIVE ACTION SHOULD BE CROSS-REFERENCED TO THE APPROPRIATE DEFICIENCY)	(X5) COMPLETION DATE
	give 1 tablet by mouth 2 times a day related to anxiety disorder. A physician order, dated 8/3/2022, indicated to monitor the following due to antianxiety medication use: observe closely for significant side effects: sedation (a state of calm or asleep), drowsiness, ataxia (drunk walk), dizziness, nausea, vomiting, confusion, headache, blurred vision, skin rash. Click Y (yes) if monitored and none of the above symptoms was observed. Click N (no) if monitored and any of the above symptoms was observed and select chart code "other/see nurse's notes" and record findings. There was no documentation found in the Nurses Notes (NN) regarding monitoring for adverse (bad) side effects of antianxiety medication. An MAR (Medicayion Administration Record), dated December 2022, indicated Resident 18 was given the medication, Buspirone HCL 5mg tablet, 1 tablet two times each day at 8:00 AM and 8:00 PM. There was no documentation to indicate side effects of this medication were monitored. An MAR, dated January 2023, indicated Resident 18 was given the medication, Buspirone HCL 5mg tablet, 1 tablet two times each day at 8:00 AM and 8:00 PM on January 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, 17, 18, 19, 20, 21, and 22. On January 15 and 23, Resident 18 had only been give the 8:00 AM dose. There was no documentation indicating side effects of this medication were monitored. 2. A physician order, dated 10/8/2022, indicated to give Venlafaxine HCl ER 150mg extended release 24-hour capsule (a medication used to treat depression), give 1 capsule by mouth 1 time a day related to major depressive disorder, single episode, unspecified.		***been identified by:*** All residents that receive psychotropic medications have the potential to be affected. Audits were completed on the orders and medication administration records of those residents on psychotropic medications that monitoring was in place and documentation was present in the progress notes if adverse side effects were present. ***Measures and systemic changes put in place to prevent reoccurrence:*** The policy on monitoring of adverse side effects of psychotropic monitoring was reviewed by the IDT team. An inservice was held with the licensed nurses and social services on how to correctly write orders to ensure side effect monitoring is being completed and documenting in the progress notes when adverse side effects are present. A performance improvement tool has been developed to audit psychotropic side effect monitoring and documentation of adverse side effects. ***Corrective Action(s) monitoring and Quality Assurance Programs:*** A performance improvement tool has been initiated that randomly checks five (5) residents to ensure that monitoring is being completed for side effects of psychotropic medications and adverse effects	

STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION	(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER	(X2) MULTIPLE CONSTRUCTION	(X3) DATE SURVEY COMPLETED
	155726	A. BUILDING 00 B. WING	01/24/2023

NAME OF PROVIDER OR SUPPLIER	STREET ADDRESS, CITY, STATE, ZIP COD
RIVER TERRACE HEALTH CARE CENTER	400 CAYLOR BLVD BLUFFTON, IN 46714

(X4) ID PREFIX TAG	SUMMARY STATEMENT OF DEFICIENCIE (EACH DEFICIENCY MUST BE PRECEDED BY FULL REGULATORY OR LSC IDENTIFYING INFORMATION	ID PREFIX TAG	PROVIDER'S PLAN OF CORRECTION (EACH CORRECTIVE ACTION SHOULD BE CROSS-REFERENCED TO THE APPROPRIATE DEFICIENCY)	(X5) COMPLETION DATE
	A physician order, dated 8/3/2022, indicated to monitor the following due to antidepressant medication use: monitor for significant side effects: drowsiness, dry mouth, blurred vision, urinary retention (unable to pass urine), tachycardia (fast heart rate), muscle tremor, agitation, headache, skin rash, photosensitivity (skin sensitive to the sun/light), excess weight gain. Click N (no) if monitored and any of the above symptoms was observed and select chart code "other/see nurse's notes" and record findings. There was no documentation found in the MAR or in the Nurses Notes (NN) regarding monitoring for adverse side effects of antidepressant medication. An MAR, dated December 2022, indicated Resident 18 was given the medication, Venlafaxine HCl ER 150mg extended release 24-hour capsule, 1 capsule every day at 8:00 AM. There was no documentation indicating side effects of this medication were monitored. A MAR, dated January 2023, indicated Resident 18 was given the medication, Venlafaxine HCl ER 150mg extended release 24-hour capsule, 1 capsule every day at 8:00 AM on January 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, and 23. There was no documentation indicating side effects of this medication were monitored. 3. A current care plan indicated Resident 18 took psychotropic medications related to major depressive disorder with behaviors. The goal indicated Resident 18 would have no side effects from the use of antipsychotic medication through the next review. The interventions iadminister ncluded medications as ordered, monitor for and		are being documented in the progress notes. This Quality Assurance Audit Tool will be completed by the Director of Nursing/ Designee Weekly for three weeks; then monthly for three months, then quarterly x three. In the event any further concerns are identified, the issue will be immediately corrected and additional training will be initiated. Results of the audit will be reviewed at the Quality Assurance Meeting at least quarterly. ***Date systemic changes will be completed:*** February 10, 2023	

STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION	(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER	(X2) MULTIPLE CONSTRUCTION	(X3) DATE SURVEY COMPLETED
	155726	A. BUILDING 00 B. WING	01/24/2023

NAME OF PROVIDER OR SUPPLIER	STREET ADDRESS, CITY, STATE, ZIP COD
RIVER TERRACE HEALTH CARE CENTER	400 CAYLOR BLVD BLUFFTON, IN 46714

(X4) ID PREFIX TAG	SUMMARY STATEMENT OF DEFICIENCIE (EACH DEFICIENCY MUST BE PRECEDED BY FULL REGULATORY OR LSC IDENTIFYING INFORMATION	ID PREFIX TAG	PROVIDER'S PLAN OF CORRECTION (EACH CORRECTIVE ACTION SHOULD BE CROSS-REFERENCED TO THE APPROPRIATE DEFICIENCY)	(X5) COMPLETION DATE
	document side effects and effectiveness, consult with pharmacy, the medical doctor was to consider dosage reduction when clinically appropriate, monitor, record and report to the medical doctor side effects and adverse reactions of psychoactive medication: unsteady gait (walking), tardive dyskinesia (uncontrollable movements of the face and body), shuffling gait, rigid muscles, shaking, frequent falls, refusal to eat, difficulty swallowing, dry mouth, depression, suicidal ideations (thoughts of harming self), social isolation (not wanting to interact with others), blurred vision, diarrhea, fatigue, insomnia (unable to sleep), loss of appetite, weight loss, muscle cramps, nausea, vomiting, behavior symptoms not usual to the resident), and social service visits as needed. A physician order, dated 12/17/2022, indicated Risperidone 0.25mg tablet (a medication used to treat psychosis, a mental disorder characterized by a disconnection from reality), give 0.5 (½) tablet by mouth 1 time a day related to major depressive disorder, recurrent, severe with psychotic symptoms. A physician order, dated 12/17/2022, indicated Risperidone 0.25mg tablet, give 1 tablet by mouth 1 time a day related to major depressive disorder, recurrent, severe with psychotic symptoms. A physician order, dated 8/3/2022, indicated antipsychotic medication use: observe closely for significant side effects: sedation, drowsiness, dry mouth, constipation, blurred vision, extra pyramidal reaction (inability to sit still, involuntary muscle contractions, tremors, stiff muscles, and involuntary facial movements), weight gain, edema (swelling from retaining fluid), postural hypotension (blood pressure drop with position change), sweating, loss of appetite, urinary retention. Click Y (yes) if monitored and none of			

STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION	(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER	(X2) MULTIPLE CONSTRUCTION	(X3) DATE SURVEY COMPLETED
	155726	A. BUILDING 00 B. WING	01/24/2023

NAME OF PROVIDER OR SUPPLIER	STREET ADDRESS, CITY, STATE, ZIP COD
RIVER TERRACE HEALTH CARE CENTER	400 CAYLOR BLVD BLUFFTON, IN 46714

(X4) ID PREFIX TAG	SUMMARY STATEMENT OF DEFICIENCIE (EACH DEFICIENCY MUST BE PRECEDED BY FULL REGULATORY OR LSC IDENTIFYING INFORMATION	ID PREFIX TAG	PROVIDER'S PLAN OF CORRECTION (EACH CORRECTIVE ACTION SHOULD BE CROSS-REFERENCED TO THE APPROPRIATE DEFICIENCY)	(X5) COMPLETION DATE
	the above symptoms was observed. Click N (no) if monitored and any of the above symptoms was observed and select chart code "other/see nurse's notes" and record findings. There was no documentation found in the Nurses Notes (NN) regarding monitoring for adverse side effects of antipsychotic medication. An MAR, dated December 2022, indicated Resident 18 was given the medication, Risperidone 0.25mg tablet, ½ tablet every day at 8:00 PM on December 18,19,20,21,22,23,24,25,26,27,28,29, 30, and 31. There was no documentation indicating side effects of this medication were monitored. An MAR, dated December 2022, indicated Resident 18 was given the medication, Risperidone 0.25mg tablet, 1 tablet every day at 8:00 AM on December 18,19,20,21,22,23,24,25,26,27,28,29, 30, and 31. There was no documentation indicating side effects of this medication were monitored. An MAR, dated January 2023, indicated Resident 18 was given the medication, Risperidone 0.25mg tablet, ½ tablet every day at 8:00 PM on January 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, 17, 18, 19, 20, 21, and 22. There was no documentation regarding the January 15 dose. There was no documentation indicating side effects of this medication were monitored. An MAR, dated January 2023, indicated Resident 18 was given the medication, Risperidone 0.25mg tablet, 1 tablet every day at 8:00 AM on January 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, and 23. There was no documentation indicating side effects of this medication were monitored.			

STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION	(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER	(X2) MULTIPLE CONSTRUCTION	(X3) DATE SURVEY COMPLETED
	155726	A. BUILDING 00 B. WING	01/24/2023

NAME OF PROVIDER OR SUPPLIER	STREET ADDRESS, CITY, STATE, ZIP COD
RIVER TERRACE HEALTH CARE CENTER	400 CAYLOR BLVD BLUFFTON, IN 46714

(X4) ID PREFIX TAG	SUMMARY STATEMENT OF DEFICIENCIE (EACH DEFICIENCY MUST BE PRECEDED BY FULL REGULATORY OR LSC IDENTIFYING INFORMATION	ID PREFIX TAG	PROVIDER'S PLAN OF CORRECTION (EACH CORRECTIVE ACTION SHOULD BE CROSS-REFERENCED TO THE APPROPRIATE DEFICIENCY)	(X5) COMPLETION DATE
	The Rounding Provider's Psychiatric Note (Nurse Practitioner), dated 1/5/2023, indicated the facility requested a visit for Resident 18 to follow up for dementia, anxiety, depression with behaviors and agitation history. Resident 18 was seen for psychiatric assessment of his described psychiatric conditions, assessment of mood and behaviors and continued evaluation of efficacy of his psychotropic medications. Staff reported Resident 18 was stable, had no weight loss or gain. Resident 18 had no reported anxiety or agitation that day. Resident 18 was described as quiet, calm with no restlessness, agitation, depression or overwhelming anxiety. Psychiatric medications included Buspar, Effexor, Aricept, and Risperidone. The Nurse Practitioner indicated she would continue to monitor Resident 18's response to the medication and note any trends in moods and behaviors, would also have staff continue to monitor for side effects from current medications. Staff was to continue to observe Resident 18 for any changes in sleep, moods, memory, appetite, and/or behaviors. Labs were reviewed for potential adverse effects to psychotropic medications. A review of Progress Notes, dated 12/24/2022 to 1/24/2023, indicated no documentation of monitoring for side effects of psychotropic medication by the facility nursing staff. In an interview, on 1/24/2023 at 10:05 AM, LPN 3 indicated side effects were to be monitored for antipsychotic, antidepressant, antianxiety, anticoagulant medications. Residents receiving antibiotics were monitored for side effects and temperature. Residents receiving Insulin had their blood glucose checked and were monitored for sign of high and low blood sugar levels.			

STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION	(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER	(X2) MULTIPLE CONSTRUCTION	(X3) DATE SURVEY COMPLETED
	155726	A. BUILDING 00 B. WING	01/24/2023

NAME OF PROVIDER OR SUPPLIER	STREET ADDRESS, CITY, STATE, ZIP COD
RIVER TERRACE HEALTH CARE CENTER	400 CAYLOR BLVD BLUFFTON, IN 46714

(X4) ID PREFIX TAG	SUMMARY STATEMENT OF DEFICIENCIE (EACH DEFICIENCY MUST BE PRECEDED BY FULL REGULATORY OR LSC IDENTIFYING INFORMATION	ID PREFIX TAG	PROVIDER'S PLAN OF CORRECTION (EACH CORRECTIVE ACTION SHOULD BE CROSS-REFERENCED TO THE APPROPRIATE DEFICIENCY)	(X5) COMPLETION DATE
	Residents were to be monitored for side effects throughout the shift and documented once a shift. Documentation was done on the MAR. In an interview, on 1/24/2023 at 10:10 AM, the Director of Nursing (DON) indicated side effects were to be monitored for antipsychotic, antidepressant, and anticoagulant medications. Monitoring should be done every shift and was to be documented on the resident's MAR. A current policy, titled Psychotropic Medication Use, dated 11/28/2017, was received from the DON on 1/24/2023 at 10:54 AM. The policy indicated, Policy "A psychotropic drug is any drug that affects brain activities associated with mental processes and behavior. These drugs include, but are not limited to, drugs in the following categories: 1. Anti-psychotic 2. Anti-depressant 3. Anti-anxiety 4. Hypnotic ... Residents who receive psychotropic medications will have their drug/medication regimen managed and monitored to promote or maintain the resident's highest practicable mental, physical, and psychosocial well-being ... Guidelines ...14. Nursing staff shall monitor for and report any of the following side effects and adverse consequences to the physician such as: a. general/anticholinergic: constipation, blurred vision, dry mouth, urinary retention, sedation b. cardiovascular: orthostatic hypotension (drop in blood pressure when changing positions), arrythmias (irregular heart rhythms), c. metabolic: increase in total cholesterol/triglycerides, unstable or poorly controlled blood sugar, weight gain d. neurologic: akathisia (feeling of muscle quivering, restlessness and inability to sit still), dystonia (disorder in which sustained or repetitive muscle contractions result in twisting and repetitive movements or abnormal fixed postures),			

STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION	(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER	(X2) MULTIPLE CONSTRUCTION	(X3) DATE SURVEY COMPLETED
	155726	A. BUILDING 00 B. WING	01/24/2023

NAME OF PROVIDER OR SUPPLIER	STREET ADDRESS, CITY, STATE, ZIP COD
RIVER TERRACE HEALTH CARE CENTER	400 CAYLOR BLVD BLUFFTON, IN 46714

(X4) ID PREFIX TAG	SUMMARY STATEMENT OF DEFICIENCIE (EACH DEFICIENCY MUST BE PRECEDED BY FULL REGULATORY OR LSC IDENTIFYING INFORMATION	ID PREFIX TAG	PROVIDER'S PLAN OF CORRECTION (EACH CORRECTIVE ACTION SHOULD BE CROSS-REFERENCED TO THE APPROPRIATE DEFICIENCY)	(X5) COMPLETION DATE
	extrapyramidal effects, akinesia (loss or impairment of movement), tardive dyskinesia (a neurological disorder characterized by involuntary movements of the face and jaw), stroke or transient ischemic attack (" mini stroke"). 15. The Physician shall respond appropriately by changing or stopping problematic doses or medications, or clearly documenting (based on assessing the situation) why the benefits of the medication outweigh the risks or suspected or confirmed adverse consequences...." 3.1-48(a)(3)			
R 0000 Bldg. 00	This visit was for a State Residential Licensure Survey. This visit included a Recertification and State Licensure Survey Survey dates: January 19, 20, 23, and 24, 2023. Facility number: 003575 Residential Census: 41 River Terrace Heath Care Center was found to be in compliance with 410 IAC 16.2-5 in regard to the State Residential Licensure Survey. Quality review completed January 25, 2023	R 0000		